Product image of Mertioscan (Mertiatide) supplied by GNH India

Mertioscan

Active Ingredient:
Mertiatide
Origin:
EU

Mertioscan (Mertiatide)

Mertiatide, the active ingredient in Mertioscan, is a pharmaceutical agent presented as an intravenous formulation for infusion use. It is currently not associated with publicly disclosed therapeutic indications.

GNH India supplies Mertioscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Rotop Pharmaka Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mertioscan (Mertiatide) is an investigational intravenous agent with no publicly disclosed approved indications.

  • No approved indication: The product is not currently authorized for specific therapeutic use.

How It Works

  • The precise mechanism of action of Mertiatide has not been publicly disclosed. Available information indicates that it is administered intravenously, but detailed pharmacodynamic or pharmacokinetic pathways have not been released by the manufacturer or regulatory agencies.

Side Effects

Adverse effect information for Mertioscan (Mertiatide) has not been publicly released.

Common Side Effects

  • None reported: No common adverse reactions have been documented in the public domain.
  • No data available: Clinical trial safety data have not been published.

Serious or Rare Side Effects

  • Unknown: Serious or rare adverse events have not been reported.
  • Not disclosed: No information on rare hypersensitivity or organ‑specific toxicity is available.

Precautions & Warnings

General precautions for intravenous agents should be observed when handling Mertioscan.

  • Patient assessment: Evaluate patient history and current condition before administration.
  • Infusion monitoring: Observe for signs of infusion‑related reactions during and after dosing.
  • Compatibility check: Verify compatibility with IV fluids and other administered drugs.
  • Contraindications: Do not use if known hypersensitivity to the product or its excipients exists.
  • Storage at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Interaction data for Mertioscan (Mertiatide) have not been made publicly available.

Major Interactions (Avoid)

  • None identified: No major drug‑drug interactions have been reported.

Moderate Interactions (Monitor Closely)

  • Potential IV compatibility issues: Assess compatibility with concurrent intravenous therapies.
  • Unknown metabolic interactions: Monitor patients receiving drugs with narrow therapeutic windows.
  • Limited data: Exercise clinical judgment when co‑administering with other investigational agents.

Frequently Asked Questions

Mertioscan (Mertiatide) is an investigational intravenous product that currently has no publicly disclosed approved therapeutic indications. It may be used in clinical research settings under controlled protocols.

The specific pharmacological mechanism of Mertiatide has not been released. As an intravenous agent, it is delivered directly into the bloodstream, but detailed target receptors or pathways remain undisclosed.

Dosage for Mertioscan is determined by the prescribing clinician based on the study protocol or therapeutic context. No standard dosing regimen is publicly available.

Safety information for Mertioscan in pregnancy or lactation has not been published. Until data are available, it should be used only if the potential benefit justifies any potential risk to the fetus or infant.

Enquiries for Mertioscan can be submitted via the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Because Mertioscan’s therapeutic class and clinical data are not publicly disclosed, direct comparisons with other intravenous drugs cannot be made. Clinicians should evaluate any available study data and consider established alternatives when making treatment decisions.

Mertioscan should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging and follow any additional handling instructions provided by the supplier.

Mertioscan is administered intravenously. The infusion should be performed by qualified healthcare professionals following aseptic technique and appropriate monitoring guidelines.

Serious risks have not been publicly reported for Mertioscan. As with any intravenous medication, potential concerns include infusion reactions, hypersensitivity, and unknown organ‑specific toxicities, which should be monitored closely.

Patients with a known hypersensitivity to Mertioscan or any of its excipients should avoid its use. Until more safety data are available, clinicians should exercise caution in populations where risk cannot be assessed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mertiatide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT